Liver-only metastatic colon cancer trial using targeted chemo
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial tests different ways to deliver chemotherapy for colon cancer that has spread only to the liver (with limited possible tiny lung spots). It looks at whether the treatment plan improves outcomes compared with another chemotherapy approach, using oxaliplatin and LV5FU2 (with or without irinotecan) plus an added targeted medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon cancer confirmed by pathology, and it has spread to the liver
- At least one liver spot is measurable on scans, and you do not have major spread elsewhere
- You know your tumor’s RAS mutation results (KRAS and NRAS testing done)
- You are 18 or older, and your general strength/condition is not too poor (WHO 0–2)
- You have not had prior chemotherapy for metastatic disease (except certain older chemo given around surgery/adjuvant treatment stopped over 12 months ago)
- Your blood counts and organ tests are within required limits (blood cells, kidney function, and liver function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus another drug (Bevacizumab) and chemotherapy (CAPEOX) for people with colorectal cancer that has spread to the liver. The goal is to shrink the tumors enough to allow surgery to remove them.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial is testing a new way to give the chemotherapy drug paclitaxel directly into the liver (through a tiny tube) along with standard systemic treatment for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to see if this targeted approach works better than standard treatment alone.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.